An analysis of the almost 5,000 abstracts set to be presented at the 2016 American Society of Hematology (ASH) meeting next month indicates this year’s hot topics in preclinical research include a spattering of new targets to watch, a growing role for nucleic acid based therapies, and a continued expansion of cell type subsets beyond the commonly used B cells and Tregs.
This year’s meeting, which takes place December 3-6 in San Diego, has a heavy emphasis on hematological malignancies, which account for more than 75% of the preclinical abstracts.
Indeed, BioCentury identified eight new therapeutic targets which all fall in oncology, two of which are new chimeric antigen receptor (CAR) T cell targets in the continually growing cancer immunology space (see “Novel targets at ASH”).
Table: Novel targets at ASH
Select new targets for hematological malignancies and other cancers presented at the 2016 American Society of Hematology (ASH) conference. Source: ASH Abstracts
|Target||Standard Indication||Research summary||Institution(s)||Abstract|
|Ankyrin repeat and sterile α motif domain containing 1B (ANKS1B)||Acute lymphoblastic leukemia (ALL)||ANKS1B was confirmed as a target upregulated by the transcription factor 3 (TCF3; E2A)-PBX homeobox 1 (PBX1) fusion found in a subset of B cell ALL patients.||Tampere University Hospital; University of California San Francisco; University of Eastern Finland; University of Helsinki; University of Tampere||4077|
|B-cell receptor-associated protein 31 (BCAP31; BAP31)||Leukemia||BCAP31 was discovered as an additional target of the protein disulfide isomerase (PDI) inhibitor PS89, and its engagement is|